Biodexa Pharmaceuticals (BDRX) EBT Margin (2015 - 2021)

Biodexa Pharmaceuticals (BDRX) has 5 years of EBT Margin data on file, last reported at 1522.69% in Q4 2021.

• For the quarter ending Q4 2021, EBT Margin rose 29185231.0% year-over-year to 1522.69%; the trailing twelve-month figure through Dec 2021 stood at 7751.34% (down 122868.0% YoY), and the FY2023 full-year result was 1964.57%, down 75026.0% from the prior year.
• EBT Margin climbed to 1522.69% in Q4 2021, from 293375.0% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 1522.69% in Q4 2021 to a low of 293375.0% in Q4 2020.
• A 3-year average of 130721.08% and a median of 113993.32% in 2020 frame the typical range for EBT Margin.
• Across the five-year window, EBT Margin plunged 28862587 bps in 2020 and soared 29185231 bps in 2021, its largest moves.
• Tracing BDRX's EBT Margin over 3 years: stood at 4749.13% in 2019, then sank by 6077 bps to 293375.0% in 2020, then jumped by 99 bps to 1522.69% in 2021.
• Business Quant data shows BDRX's EBT Margin at 1522.69% in Q4 2021, 293375.0% in Q4 2020, and 223237.5% in Q3 2020.